The Mayne Pharma Group Ltd (ASX: MYX) share price will be one to watch on Monday following the release of a positive update by the pharmaceutical company.
What did Mayne Pharma announce?
This morning Mayne Pharma announced that it has entered into a long-term supply agreement with Novast Laboratories for 13 U.S. generic oral contraceptive products. This includes five new products not previously marketed by the company.
Novast Laboratories is a pharmaceutical company based in Nantong, China. It develops and commercialises generic drugs for global markets. Novast has a significant number of products approved by the U.S. Food and Drug Administration (FDA), including hormone products and sustained-release oral dosage forms.
According to the release, four of the additional products are FDA approved and include generic equivalents of two of the highest prescribed oral contraceptive products in the United States.
These are Ortho Cyclen and Ortho Tricyclen, as well as Loestrin 24 FE and Desogen. The fifth new product included in the agreement is still pending review with the FDA.
Mayne Pharma’s CEO, Scott Richards, commented: “We are very pleased to have partnered with Novast, who have an outstanding quality track record manufacturing and supplying oral contraceptives to the US market. This transaction expands our women’s health portfolio and secures supply on more favourable terms of eight products previously acquired from Teva Pharmaceuticals to continue to drive growth of our women’s health franchise.”
What is the market opportunity?
The company notes that, according to IQVIA, the annual U.S. market sales for the five additional products were US$500 million, with more than 1.3 billion tablets sold annually.
This agreement has given Mayne Pharma’s women’s health portfolio a major boost in respect to its market opportunity.
Mr Richards said: “Mayne Pharma’s women’s health portfolio today includes 27 marketed and pipeline products, including a novel oral contraceptive E4/DRSP and two generic contraceptive products targeting markets with sales of US$1.2 billion and targeted to launch in FY21.”
Finally, with the Mayne Pharma share price down 22% since the start of the year, shareholders will no doubt be hoping this is the catalyst to narrowing this decline and ultimately taking its shares higher for the year in the near future.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
- Why the Mayne Pharma share price is climbing today
- These 5 ASX shares saw the biggest losses last week
- ASX 200 Weekly Wrap: ASX back in the green
- These were the worst performers on the ASX 200 last week
- ASX 200 finishes higher by 0.8%, Carsales share price driven up by FY20 guidance
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Mayne Pharma share price on watch after announcing major Novast Laboratories agreement appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3f4zGA5
Leave a Reply